secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-11-22T23:59:59+00:00
Accession:  0000950170-23-065895
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics shareholders approve increase in authorized common stock and preferred stock conversion
--------------------------------------------------------------------------------

- Shareholders approved amendment to increase authorized common stock from 490M to 800M shares on Nov 22, 2023.
- Proposal 1 received 40,768,042 votes for, 1,732,365 against, and 375,532 abstentions.
- Shareholders also approved potential issuance >19.99% of outstanding common stock upon conversion of Series A Preferred Stock.
- Proposal 2 received 33,420,475 votes for, 352,390 against, 376,812 abstentions, and 8,726,262 broker non-votes.
- The conversion involves Series A-1, A-2, and A-3 Convertible Preferred Stock under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023065895/0000950170-23-065895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023065895/sabs-20231122.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-065895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer